Oxford BioDynamics PLC (OBD), the UK-based epigenetics company, has disclosed that Premier Miton Group plc crossed the 5% voting rights notification threshold on 10 November 2026. The TR-1 regulatory filing, submitted to Oxford BioDynamics on 11 November 2026, confirms Premier Miton Group now holds 5.602299% of the company's voting rights. The disclosure is a standard major shareholding notification required under the UK's Disclosure Guidance and Transparency Rules, and represents a notable institutional position in the AIM-listed biotech firm.

Key Points

  • Oxford BioDynamics PLC (OBD) — AIM-listed UK epigenetics company (ISIN: GB00BD5H8572)
  • Premier Miton Group plc has crossed the 5% voting rights threshold, now holding 5.602299% of OBD's voting rights
  • 753,000,000 voting rights are held directly; the threshold was crossed on 10 November 2026, with no prior notification on record
  • Investors may watch for any further changes to Premier Miton's position and any subsequent strategic developments at Oxford BioDynamics

Premier Miton Group Acquires 753 Million Voting Rights in Oxford BioDynamics

According to the TR-1 form filed on 11 November 2026, Premier Miton Group plc, a London-registered investment management group, directly holds 753,000,000 voting rights in Oxford BioDynamics PLC, equating to 5.602299% of total voting rights. The notification confirms that all holdings are in the form of shares carrying direct voting rights under DTR5.1, with no financial instruments or indirect holdings recorded. This is marked as a first notification, with no previous position on record from Premier Miton, indicating this threshold was crossed for the first time on 10 November 2026.

How Premier Fund Managers Ltd Holds the OBD Stake Within the Premier Miton Structure

The TR-1 disclosure sets out the full chain of controlled undertakings through which the voting rights are effectively held. The ultimate controlling entity is Premier Miton Group plc, with the stake held operationally through Premier Asset Management Midco Ltd, Premier Asset Management Holdings Ltd, Premier Asset Management Limited, Premier Investment Group Ltd, and ultimately Premier Fund Managers Ltd, which records the 5.602299% position. This structure reflects standard asset management group ownership, where fund-level holdings are attributed back to the parent group for major shareholding notification purposes under UK transparency rules.

Oxford BioDynamics: Epigenetics Technology and Institutional Investor Interest

Oxford BioDynamics is a UK-based biotechnology company focused on epigenomics, using its proprietary EpiSwitch technology platform to develop biomarkers and companion diagnostics. The company operates within the life sciences sector and has pursued partnerships with pharmaceutical and clinical research organisations. The entry of an institutional asset manager of Premier Miton Group's scale above the 5% disclosure threshold may attract attention from investors monitoring the shareholder register, though the announcement itself contains no commentary on strategic intent, and the company did not disclose any associated transaction value or commercial development linked to this filing.

Regulatory Context of the TR-1 Major Shareholding Notification

Under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules, any person whose holding of voting rights in a UK-listed issuer crosses the 5% threshold is required to notify the issuer promptly. Oxford BioDynamics confirmed it was notified on 11 November 2026, one day after the threshold was crossed. The TR-1 form was completed in Guildford, UK. Investors should note that this filing reflects a regulatory obligation rather than any voluntary corporate announcement, and no additional guidance or operational information was provided alongside the notification.